Compare MXCT & RDCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXCT | RDCM |
|---|---|---|
| Founded | 1999 | 1985 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.8M | 168.1M |
| IPO Year | 2021 | 1999 |
| Metric | MXCT | RDCM |
|---|---|---|
| Price | $1.56 | $10.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $4.11 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 1.4M | 45.6K |
| Earning Date | 11-10-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,026,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.53 | $6.56 |
| P/E Ratio | ★ N/A | $16.35 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $9.40 |
| 52 Week High | $1.81 | $16.74 |
| Indicator | MXCT | RDCM |
|---|---|---|
| Relative Strength Index (RSI) | 63.38 | 48.20 |
| Support Level | $1.17 | $9.94 |
| Resistance Level | N/A | $10.48 |
| Average True Range (ATR) | 0.12 | 0.30 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 75.12 | 32.38 |
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.